SPECTROPHOTOMETRIC DETERMINATION OF (7-N-BUTYL-3-METHYLXANTHIN-8-YL)DIETHYLAMINOETHYLAMMONIUM
DOI:
https://doi.org/10.11603/2312-0967.2021.4.12705Keywords:
(7-n-butyl-3-methylxanthin-8-yl)diethylaminoethylammonium oxalate, quantitative determination, UV spectrophotometry, validationAbstract
The aim of the work. Development and validation of UV spectrophotometric method for the quantitative determination of (7-n-butyl-3-methylxanthin-8-yl) diethylaminoethylammonium oxalate.
Materials and Methods. The object of study is a substance of (7-n-butyl-3-methylxanthin-8-yl)diethylaminoethylammonium oxalate. The solvent - purified water. Analytical equipment: Specord 200 spectrophotometer (Analytic Jena AG, Germany), electronic laboratory scales (RADWAG XA 210.4Y), the ultrasonic bath (Sonorex Digitec DT100H), measuring utensils (Class A).
Results and Discussion. The band observed at 265 - 325 nm with a maximum of light absorption at 296 nm was selected to develop the method for the quantitative determination of this substance. According to the requirements of the SPU, the forecast of complete uncertainty of the methodology was calculated, as well as the validation of the methodology according to such validation characteristics as range of application, linearity, precision, accuracy and robustness. The range of application of the technique is in the range of 75-125%. The calculated numerical values of linear dependence indicate that the method is linear in the whole range of application methods (r = 0.9999).The calculated confidence interval ∆x does not exceed the maximum allowable uncertainty of the analysis ΔAs, which indicates that the method is accurate at the level of convergence. It is proved that the systematic error δ, which is introduced by the instability of the analyzed solution, does not exceed the critical value of maxδ, ie the solution remains stable for at least 1 hour.
Conclusion. The UV spectrophotometric method for the quantitative determination of (7-n-butyl-3-methylxanthin-8-yl) diethylaminoethylammonium oxalate has been developed and validated.
References
Flick A, Leverett C, Ding H, McInturff E, Fink S, Helal C et al. Synthetic Approaches to New Drugs Approved during 2018. Journal of Medicinal Chemistry. 2020;63(19):10652-704.
Tm K, Oi P, Yu K. Research of the synthetic, physical and chemical properties of 3-alkylsulfonyl-5-(Chinoline-2-yl, 2-hydroxychinoline-4-yl)-4-r1-2,4-dihydro-3n-1,2,4-triazoles. Asian Journal of Pharmaceutical and Clinical Research. 2016;10(1):81.
Bihdan O, Parchenko V. Chemical modification and Physicochemical properties of new derivatives 5-(thiophen-3-ilmethyl)-4-R1-1,2,4-triazole-3-thiol. Research Journal of Pharmacy and Technology. 2021;14(9):4621-9.
Krasovska N, Stavytskyi V, Nosulenko I, Kholodniak S, Antypenko O, Voskoboinik O et al. Pyrrol[1,2-a]azolo-(azino-)[c]quinazolines and their derivatives as 15-LOX inhibitors: Design, in vitro studies and QSAR-analysis. Journal of Research in Pharmacy. 2021; 25(5):540-8.
Gotsulya A, Zazharskyi V, Davydenko P. Synthesis and antituberculosis activity of N'-(2-(5-((theophylline-7'-yl)methyl)-4-R-4Н-1,2,4-triazole-3-ylthio)acetyl)isonicotinohydrazides. Zaporozhye Medical Journal. 2018;4(109):578-83.
Gotsulya A. Actoprotective properties of 7'-((3-thio-4-methyl-4H-1,2,4-triazole-5-yl)methyl)theophylline derivatives. Zaporozhye Medical Journal. 2016;3(96):104-7.
Yang Y, Li Y, Zhou W, Chen Y, Wu Q, Pan Y et al. Exploring the structural determinants of novel xanthine derivatives as A2B adenosine receptor antagonists: a computational study. Journal of Biomolecular Structure and Dynamics. 2018;37(13):3467-81.
Basu S, Barawkar D, Ramdas V, Waman Y, Patel M, Panmand A et al. A 2B adenosine receptor antagonists: Design, synthesis and biological evaluation of novel xanthine derivatives. European Journal of Medicinal Chemistry. 2017;127:986-96.
Basu S, Barawkar D, Ramdas V, Patel M, Waman Y, Panmand A et al. Design and synthesis of novel xanthine derivatives as potent and selective A 2B adenosine receptor antagonists for the treatment of chronic inflammatory airway diseases. European Journal of Medicinal Chemistry. 2017;134:218-29.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Pharmaceutical Review / Farmacevtičnij časopis
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The authors who publish their materials in this journal agree with the following terms:
- Authors reserve the right to authorship of their work and assign to the journal the right to first publish this work under the terms of the Creative Commons Attribution License, which allows other persons to freely distribute the published work with a mandatory reference to the authors of original work and the first publication of work in this journal
. - Authors have the right to make independent extra-exclusive work agreements in the form they are published by this journal (for example, posting work in an electronic repository of an institution or publishing as part of a monograph), provided that the link to the first publication of the work in this journal is maintained.
Journal policy allows and encourages publication of manuscripts on the Internet (for example, in institutions repositories or on personal websites), both before the publication of this manuscript and during its editorial review, as it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the citation of the published work (see The Effect of Open Access).
